Compare Alcon AG (ALC) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Liberty Global Ltd Class C — how do they compare? Alcon AG trades at $75 (market cap $36.44B), while Liberty Global Ltd Class C trades at $10.14 (market cap $3.48B). The key difference: Alcon AG is far larger — about 10.5× Liberty Global Ltd Class C's market cap, and Alcon AG pays a 0.48% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals.
| ALC | LBTYK | |
|---|---|---|
Market Cap | $36.44B | $3.48B |
Sector | Health | Technology |
52-Week High | $90.12 | $12.67 |
52-Week Low | $62.02 | $9.59 |
Enterprise Value | $40.28B | $10.13B |
Dividend Yield | 0.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.59, down slightly by 0.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $86.67 implying 17.8% upside. Recent Q2 2026 earnings beat estimates with EPS of $0.84 versus $0.77 expected, and the company raised its 2026 profitability outlook, driving positive investor sentiment. Revenue growth has been steady, reaching $10.40 billion in 2025, though net income margin dipped to 5.92%.
The outlook is positive given strong earnings beats, raised guidance, and bullish analyst ratings, but risks include elevated P/E of 57.52, high RSI levels suggesting overbought conditions, and margin pressures from rising costs. Institutional ownership trends and recent collaborations, like with RxSight, support growth, yet macroeconomic and competitive factors warrant caution.
LBTYK trades at $10.105, up 1.15% on the day, but technical indicators signal a bearish trend. The company reported mixed quarterly earnings, with a Q1 2026 beat but Q2 2026 miss, while full-year 2025 showed a net loss of $7.14B. Positive cash flow of $264.80M in 2025 and strategic moves like the Ziggo Group spin-off planned for 2027 highlight management's focus on unlocking value. Analyst sentiment is largely bullish with 69% buy ratings, citing sum-of-the-parts potential.
The outlook hinges on execution of asset monetizations and the Ziggo listing, offering upside if successful, but persistent losses and competitive pressures pose risks. Investors should weigh the high analyst optimism against fundamental weaknesses and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
